BH3 mimetics’ potential for NSCLC treatment has already been tested in KRAS and EGFR-mutated tumors [15–17], but alterations in the BCL-2 family in ALK-rearranged NSCLC is still not fully understood. This evidence concerns the gene KRAS and non-small cell lung carcinoma.